New Targets for PET Imaging of Myeloma

Recent advances in the treatment of multiple myeloma (MM) have increased the need for accurate diagnosis and detection of minimal residual disease (MRD), disease characterization and localization, and response evaluation and prognostication. Positron emission tomography (PET)/computed tomography (CT...

Full description

Saved in:
Bibliographic Details
Published in:Hemato 2021-12, Vol.2 (4), p.727-738
Main Authors: Revheim, Mona-Elisabeth, Stokke, Caroline, Nørgaard, Jakob Nordberg, Phillips, Hilde Feiring, Sherwani, Alexander Gul, Schjesvold, Fredrik, Connelly, James P.
Format: Article
Language:English
Subjects:
[11C]methionine
[18F]FDG
[18F]fluciclovine
[68Ga]Ga-pentixafor
Amino acids
Anemia
Biopsy
Bone marrow
Brain cancer
Disease
Medical prognosis
Multiple myeloma
Patients
PET/CT
Plasma
Prostate cancer
Radiation therapy
Remission (Medicine)
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent advances in the treatment of multiple myeloma (MM) have increased the need for accurate diagnosis and detection of minimal residual disease (MRD), disease characterization and localization, and response evaluation and prognostication. Positron emission tomography (PET)/computed tomography (CT) imaging combines molecular and morphological information and has been shown to be especially valuable in this disease. The most frequently used PET tracer in MM is the glucose analog 18F-fluorodeoxyglucose ([18F]FDG). [18F]FDG PET/CT has a sensitivity for detection of MM between 80% to 100% and is currently the main imaging modality for assessing treatment response and for determining MRD. However, 18F-FDG PET/CT has some limitations, and imaging with alternative tracers that may overcome these constraints should be further explored. This article discusses new targets for PET/CT imaging in the assessment of MM.
ISSN:2673-6357
2673-6357
DOI:10.3390/hemato2040049